Exhibit 99.1 Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages IRVING, TX – November 12, 2024 – Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September ...

Shares of biote Corp. (BTMD) have gained 2% over the past four weeks to close the last trading session at $5.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $9.59 indicates a potential upside of 88%.The mean estimate comprises five short-term price targets with a standard deviation of $1.81. While the lowest estimate of $7 indicates a 37.3% increase from the current price le ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuat ...

biote Corp. (NASDAQ:BTMD) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Szymon Serowiecki – Investor Relations Terry Weber – Chief Executive Officer Bob Peterson – Chief Financial Officer Conference Call Participants Les Sulewski – Truist Securities Jonna Kim – TD Cowen Richard Magnusen – B. Riley Securities George Kelly – ROTH Capital Kaumil Gajrawala – Jefferies Operator Good day, and welcome to the Biote Second Quarter 2024 Earnings Conference Call. All participants will ...

Exhibit 99.1 Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance IRVING, TX – August 8, 2024 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Finan ...

Shares of biote Corp. (BTMD) have gained 14.8% over the past four weeks to close the last trading session at $7.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $9.27 indicates a potential upside of 25.4%. Price, Consensus and EPS Surprise While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets ha ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. - ...

The sharp upsurge in Biote's shares can be attributed to the company's announcement that it has signed a binding term sheet with stockholder Marci Donovitz, the ex-wife of founder Gary Donovitz, to resolve her legal claims. She claims that the blank-check company deal that took Biote public was manipulated against the founder's best interests. As part of the settlement, Biote is repurchasing Marci Donovitz's 8.3 million shares at an average price of $7.23 for an aggregate of $60 million. The stock currently ...

• our ability to retain existing key management, to integrate recent hires and to attract, retain and motivate qualified personnel; • the overall strength and stability of the economies in the markets in which we operate or intend to operate in the future; and • regulatory, legislative and political changes. Unfavorable changes in any of these or other factors, most of which are beyond our control, could materially and adversely affect our business, prospects, financial condition, and results of operations. ...

Company Participants Conference Call Participants Operator Simon Serowiecki Simon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Marc Beer - Executive Chairman Ross McQuivey - Chief Medical Officer Les Sulewski - Truist Securities Jonna Kim - TD Cowen Kaumil Gajrawala - Jefferies George Kelly - ROTH MKM Good day, and welcome to the Biote First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded ...